Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jaguar Health Inc JAGX

Healthcare
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing... see more

Recent & Breaking News (NDAQ:JAGX)

Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Accesswire March 30, 2023

Jaguar Health Reports 2022 Financial Results - Prescription Revenues up 179% to $11.9 Million

Accesswire March 27, 2023

Jaguar Health Announces Time Change for March 27th Investor Webcast to 8:00 AM EDT

Accesswire March 24, 2023

Leading Cancer Patient Advocate Kelly Shanahan, M.D., Joins Jaguar Health's Scientific Advisory Board

Accesswire March 23, 2023

Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates

Accesswire March 21, 2023

Jaguar Health Celebrates U.N. International Day of Forests with Milestone of Providing Income to 20,000+ People Living in Tropical Rainforest Communities

Accesswire March 15, 2023

Jaguar Health Leveraging AI to Support Patient Access to Mytesi, the Company's FDA-Approved Prescription Drug

Accesswire March 13, 2023

Jaguar Health to Present at BioTrinity 2023 Conference's R&D Spotlight on Rare Diseases

Accesswire March 2, 2023

FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US

Accesswire February 28, 2023

Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer

Accesswire February 23, 2023

Jaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea

Accesswire February 21, 2023

Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.

Accesswire February 9, 2023

Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement

Accesswire February 8, 2023

Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar's 2023 Focus on Human Drug Development

Accesswire February 1, 2023

Jaguar Health Engages Shareholder Intelligence Services, LLC (ShareIntel) to Monitor Trading Activity in Effort to Identify Possible Illegal Short Selling

Accesswire February 1, 2023

Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise

Accesswire January 30, 2023

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Accesswire January 27, 2023

Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & Europe

Accesswire January 26, 2023

Jaguar Health Announces Completion of Key Milestone in Process of Establishing Indena S.p.A. as a Reliable Approved Crofelemer Manufacturer

Accesswire January 25, 2023

Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences

Accesswire January 23, 2023